OxyContin
(Oxycodone Hydrochloride)ApprovedSmall molecule
Oxycodone is a strong painkiller used to treat moderate to severe pain, such as pain from cancer, injury, or surgery. It works by changing how the brain and nervous system respond to pain.[2] OxyContin is currently approved and in use across 7 indications[4].[1]
OxyContin is one of 168 small molecule programs targeting Pain. It is currently in Approved.
7
Indications
26
Total Trials
4
Active Trials
167
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
193 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1OxyContin
PPurdue Pharma LP
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Nucynta
CCollegium Pharmaceutical, Inc.
Phase 3
Tramadol Plus Acetaminophen
Johnson & JohnsonPhase 3
Zohydro Er
TevaPhase 3
Dextromethorphan Hydrobromide
Boehringer IngelheimPhase 3
Buprenorphine IV
PPurdue Pharma LP
Phase 3
Opana
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
MS Contin
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Oxycodone9 trials
Show 6 more trials
Single Dose2 trials
Cancer Pain2 trials
Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 4·NCT00378937·30 enrolled
Shoulder Arthroplasty2 trials
10 more indications
Efficacy and Safety1 trial
Abuse Potential1 trial
Head and Neck Cancer1 trial
Post Operative Pain1 trial
Bone Fracture1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — OxyContin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Oxycodone Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Mu Opioid Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- PPurdue Pharma LP